Structure, Function, and Diseases of Fibronectin and Vitronectin

玻连蛋白（Vitronectin）是1983年发现的一种新的血浆糖蛋白，具有细胞铺展、血液凝固和补体作用等生物学活性，我们对它的结构和功能进行了研究，主要结果如下：1.建立了人血玻连蛋白浓度的免疫学测定方法。(1)在肝衰竭患者中，人血浆中玻连蛋白的浓度非常低。(2)根据玻连蛋白的65 kDa和75 kDa多肽的比例，人血液样品可分为三种不同的玻连蛋白类型。(3)迄今为止，未发现与该血型相关的疾病。2.我们已经成功地从牛、马、鸡、猪和兔的血浆或血清中纯化玻连蛋白，与我们最近开发的用于人血浆的相同新方法相同。3.我们已经克隆了4个产生抗人玻璃体切割单克隆抗体的小鼠杂交瘤，M1，M2，M4和M5。利用这些单克隆抗体，玻连蛋白的胶原结合结构域建议存在于玻连蛋白分子的N-末端的一半。4.我们已经纯化了一些玻连蛋白的甲酸裂解片段。这些片段之一似乎对应于胶原结合结构域。

Vitronectin discovered in 1983 is a new plasma glycoprotein, which has been shown to have biological activities concerning cell spreading, blood coagulation, and complement action.We have investigated the structure and function of vitronectin and the results we have obtained are as follows.1. We have developed the method to measure vitronectin concentration in human blood immunologically. (1) The concentration of vitronectin in human plasma was remarkably low in the person having liver failures. (2) Human blood samples could be classified into three distinct vitronectin types depending on the ratios of 65 kDa and 75 kDa polypeptides of vitronectin. (3) The vitronection blood type was not related with any deseases tested so far. 2. We have succeeded in purification of vitronectin from plasma or sera of bovine, horse, chicken, porcine, and rabbit with the same new procedure developed for human plasma very recently by us. 3. We have cloned 4 mouse hybridoma producing anti-human vitronection monoclomal antibodies, M1, M2, M4, and M5. Using these monoclonal antibodies, collagen-binding domain of vitronectin was suggested to exist on the N-terminal half of vitronectin molecule. 4. We have purified a few vitronectin fragments cleaved with formic acid. One of these fragments seemed to correspond to the collagen-binding domain.